ArticleThe Journal of clinical investigation2000
Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection.
Article in The Journal of clinical investigation, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 251 citations in OpenAlex.
- Evolution of CCR1 and CCR1L1 reveals complex duplication scenarios in Muroids and Ruminants.Immunogenetics · 2026Article
- Core signature of rejection-associated cytokines and chemokines in endomyocardial biopsies after heart transplantation.Frontiers in cardiovascular medicine · 2025Article
- Immune characteristics of kidney transplant recipients with acute respiratory distress syndrome induced by COVID-19 at single-cell resolution.Respiratory research · 2024Article
- Development of a High-Color Flow Cytometry Panel for Immunologic Analysis of Tissue Injury and Reconstruction in a Rat Model.Cells, tissues, organs · 2023Article
- The role of macrophages in thermal injury.International journal of burns and trauma · 2022Review
- Vascular Signaling in Allogenic Solid Organ Transplantation - The Role of Endothelial Cells.Frontiers in physiology · 2020Review
- Histone/protein deacetylase 11 targeting promotes Foxp3+ Treg function.Scientific reports · 2017Article
- The chemokines CCR1 and CCRL2 have a role in colorectal cancer liver metastasis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Chemokines and Chemokine Receptors in the Development of Lupus Nephritis.Mediators of inflammation · 2016Review
- The chemokine receptor CCR1 is constitutively active, which leads to G protein-independent, β-arrestin-mediated internalization.The Journal of biological chemistry · 2013Article
- Chemokines in innate and adaptive granuloma formation.Frontiers in immunology · 2013Article
- Cytomegalovirus CC chemokine promotes immune cell migration.Journal of virology · 2012Article
- Macrophages: contributors to allograft dysfunction, repair, or innocent bystanders?Current opinion in organ transplantation · 2012Review
- Mechanisms and mediators of inflammation: potential models for skin rejection and targeted therapy in vascularized composite allotransplantation.Clinical & developmental immunology · 2012Review
- Innate immunity and resistance to tolerogenesis in allotransplantation.Frontiers in immunology · 2012Article
- Inhibition of chemokine-glycosaminoglycan interactions in donor tissue reduces mouse allograft vasculopathy and transplant rejection.PloS one · 2010Article
- CC chemokine receptor-1 activates intimal smooth muscle-like cells in graft arterial disease.Circulation · 2009Article
- Chemokines and transplant vasculopathy.Circulation research · 2008Review
- Article
- Deletion of the chemokine receptor CCR1 prolongs corneal allograft survival.Investigative ophthalmology & visual science · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
Although mononuclear cell infiltration is a hallmark of cellular rejection of a vascularized allograft, efforts to inhibit rejection by blocking leukocyte-endothelial cell adhesion have proved largely unsuccessful, perhaps in part because of persistent generation of chemokines within rejecting grafts. We now provide, to our knowledge, the first evidence that in vivo blockade of specific chemokine receptors is of therapeutic significance in organ transplantation. Inbred mice with a targeted deletion of the chemokine receptor CCR1 showed significant prolongation of allograft survival in 4 models. First, cardiac allografts across a class II mismatch were rejected by CCR1(+/+) recipients but were accepted permanently by CCR1(-/-) recipients. Second, CCR1(-/-) mice rejected completely class I- and class II-mismatched BALB/c cardiac allografts more slowly than control mice. Third, levels of cyclosporin A that had marginal effects in CCR1(+/+) mice resulted in permanent allograft acceptance in CCR1(-/-) recipients. These latter allografts showed no sign of chronic rejection 50-200 days after transplantation, and transfer of CD4(+) splenic T cells from these mice to naive allograft recipients significantly prolonged allograft survival, whereas cells from CCR1(+/+) mice conferred no such benefit. Finally, both CCR1(+/+) and CCR1(-/-) allograft recipients, when treated with a mAb to CD4, showed permanent engraftment, but these allografts showed florid chronic rejection in the former strain and were normal in CCR1(-/-) mice. We conclude that therapies to block CCR1/ligand interactions may prove useful in preventing acute and chronic rejection clinically.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.